Medicines Co wins generic portfolio in Angiomax patent settlement with APP
This article was originally published in Scrip
Executive Summary
The Medicines Company retains US protection of its key cash earning asset, the anticoagulant Angiomax (bivalirudin for injection), until mid-2019 following a patent settlement with APP Pharmaceuticals, a subsidiary of Fresenius Kabi. And the hospital specialist company boosted its product portfolio with a set of 10 generic drug licensed from APP.